Xenon Pharmaceuticals (XENE)
(Real Time Quote from BATS)
$41.52 USD
+0.81 (1.99%)
Updated Oct 16, 2024 11:22 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
XENE 41.52 +0.81(1.99%)
Will XENE be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for XENE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for XENE
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
XENE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
Other News for XENE
Xenon Pharmaceuticals resumed with an Outperform at Raymond James
Stifel Nicolaus Remains a Buy on Xenon (XENE)
Xenon Pharmaceuticals Inc (XENE) Q2 2024 Earnings Call Highlights: Strategic Advances and ...
Xenon Pharmaceuticals participates in a conference call with JPMorgan
Xenon Pharmaceuticals participates in a conference call with JPMorgan